Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health ... headquartered in Rahway, New Jersey.

Merck & Co Inc (NYSE:MRK) is making significant progress in its pipeline, with 20 potential new growth drivers, many with blockbuster potential. The Animal Health business delivered strong ...

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling more than $90 million in 2022 and ...

Management expects mid-to-high single-digit growth in Merck's total business outside ... vaccines, and Animal Health. KEYTRUDA sales grew 21% to $7.8B, with increased uptake in earlier-stage ...

New negotiated prices for that first round of drugs go into effect in 2026. Merck's animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.4 ...

Ltd (QVPL) for ₹460 crore in an all-cash deal to diversify into the specialty animal health, nutrition, and feed additives business. The transaction reflects an upfront acquisition of a 65% ...

driven by areas such as oncology and animal health. Still, the focus on Gardasil’s slowdown highlights a larger issue for Merck: its growing dependence on its other big blockbuster, cancer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...